Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.62 |
| ▸ | RARB | P10826 | 4/20 | 0.50 |
| ▸ | RARA | P10276 | 1/20 | 0.47 |
| ▸ | RARG | P13631 | 1/20 | 0.47 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.44 |
| ▸ | NSD2 | O96028 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.41 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 2/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17225165 | 0.96 | TSHR (0.69) | TSHRHSD17B10RARBRARARARG | |
| SCHEMBL14526072 | 0.92 | TSHR (0.57) | TSHRHSD17B10RARBHRH3NSD2 | |
| SCHEMBL7913848 | 0.92 | TSHR (0.54) | TSHRHSD17B10RARBRARARARG | |
| SCHEMBL9406878 | 0.92 | TSHR (0.54) | TSHRHSD17B10RARBRARARARG | |
| SCHEMBL29637013 | 0.92 | TSHR (0.54) | TSHRHSD17B10RARBRARARARG | |
| SCHEMBL29306086 | 0.90 | TSHR (0.56) | TSHRHSD17B10RARBRARARARG | |
| SCHEMBL14175170 | 0.89 | RARB (0.59) | TSHRHSD17B10RARBRARARARG | |
| SCHEMBL29306099 | 0.88 | TSHR (0.54) | TSHRHSD17B10RARBHRH3NSD2 | |
| SCHEMBL8377971 | 0.88 | TSHR (0.64) | TSHRHSD17B10RARBRARARARG | |
| SCHEMBL17946137 | 0.86 | CYP2A6 (0.58) | TSHRHSD17B10KIF11HRH3NSD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228878-A1 | COMPOUND, LIQUID CRYSTAL COMPOSITION, AS WELL AS LIQUID CRYSTAL DISPLAY ELEMENT, SENSOR, LIQUID CRYSTAL LENS, OPTICAL COMMUNICATION EQUIPMENT, AND ANTENNA EACH USING THE SAME | DIC CORPORATION (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20240228878-A1 | COMPOUND, LIQUID CRYSTAL COMPOSITION, AS WELL AS LIQUID CRYSTAL DISPLAY ELEMENT, SENSOR, LIQUID CRYSTAL LENS, OPTICAL COMMUNICATION EQUIPMENT, AND ANTENNA EACH USING THE SAME | DIC CORPORATION (JP) | 2024-07-11 | — | — | US | disclosed |
| US-20180171229-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | DIC CORPORATION (JP) | 2018-06-21 | — | — | US | disclosed |
| US-20180171234-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE USING THE SAME | DIC CORPORATION (JP) | 2018-06-21 | — | — | US | disclosed |
| US-20180134961-A1 | LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE USING THE SAME | DIC CORPORATION (JP) | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228878-A1 | COMPOUND, LIQUID CRYSTAL COMPOSITION, AS WELL AS LIQUID CRYSTAL DISPLAY ELEMENT, SENSOR, LIQUID CRYSTAL LENS, OPTICAL COMMUNICATION EQUIPMENT, AND ANTENNA EACH USING THE SAME | TTI2, CCT4, CCT2 | TSHR 196/4885HSD17B10 4365/4885RARB 1680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.